Bristol Myers Squibb (BMY)
(Real Time Quote from BATS)
$42.85 USD
+0.18 (0.42%)
Updated Jul 23, 2024 03:46 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMY 42.85 +0.18(0.42%)
Will BMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Other News for BMY
UK dividends calendar - next 7 days
UK dividends calendar
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline
Bristol Myers price target lowered by $8 at Deutsche Bank, here's why